Florent Puisset1,2,3, Laurence Bigay-Game4, Marie Noëlle Paludetto5,6, Audrey Martel5, Sophie Perriat7, Audrey Rabeau4, Jean Marie Canonge7, Julien Mazieres4,8. 1. Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, Toulouse, France. Puisset.florent@iuct-oncopole.fr. 2. CRCT (Cancer Research Centre of Toulouse), Université de Toulouse, Inserm UMR 1037, Université Paul Sabatier, 31059, Toulouse Cedex 9, France. Puisset.florent@iuct-oncopole.fr. 3. Pharmacie, Institut Universitaire du Cancer Toulousain-Oncopole, 1 Avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France. Puisset.florent@iuct-oncopole.fr. 4. Thoracic Oncology Department, Larrey Hospital, University Hospital Toulouse, Toulouse, France. 5. Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, Toulouse, France. 6. CRCT (Cancer Research Centre of Toulouse), Université de Toulouse, Inserm UMR 1037, Université Paul Sabatier, 31059, Toulouse Cedex 9, France. 7. Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, University Hospital Toulouse, Toulouse, France. 8. Université Paul Sabatier, Toulouse, France.
Abstract
PURPOSE: Hydration is needed before and after cisplatin infusion for reducing the risk of nephrotoxicity. Even though there is no standard regimen, patients receive mostly intravenous hydration before and after cisplatin leading hospitalization during at least one night. Since the feasibility has been published, oral hydration after cisplatin was implemented in our practice. The safety of this new way of hydration needs to be assessed in clinical practice. METHODS: We collected medical records from patients treated by cisplatin for lung cancer in our unit between 2010 and 2016. We retrospectively analyzed the incidence of cisplatin induced nephrotoxicity between after and before the change of hydration regimen. RESULTS: Our patient cohort included 241 patients hydrated by intravenous regimen (IV/IV group) and 276 patient hydrated by intravenous and oral regimen (IV/PO group). Grade ≥ 1 nephrotoxicity occurred in 39.4 and 25.7% in the IV/IV and IV/PO groups respectively (p = 0.001). Age over 70 at baseline was a predictive factor for nephrotoxicity, but not estimated glomerular filtration rate nor cisplatin-associated drugs. After a multivariate analysis, age remained a predictive factor for nephrotoxicity and IV/PO hydration associated with a decrease in nephrotoxic risk. CONCLUSION: The implementation of oral hydration in our practice was not associated with an increase in nephrotoxicity. Our observation based on large data from clinical practice shows that oral hydration after cisplatin is safe.
PURPOSE: Hydration is needed before and after cisplatin infusion for reducing the risk of nephrotoxicity. Even though there is no standard regimen, patients receive mostly intravenous hydration before and after cisplatin leading hospitalization during at least one night. Since the feasibility has been published, oral hydration after cisplatin was implemented in our practice. The safety of this new way of hydration needs to be assessed in clinical practice. METHODS: We collected medical records from patients treated by cisplatin for lung cancer in our unit between 2010 and 2016. We retrospectively analyzed the incidence of cisplatin induced nephrotoxicity between after and before the change of hydration regimen. RESULTS: Our patient cohort included 241 patients hydrated by intravenous regimen (IV/IV group) and 276 patient hydrated by intravenous and oral regimen (IV/PO group). Grade ≥ 1 nephrotoxicity occurred in 39.4 and 25.7% in the IV/IV and IV/PO groups respectively (p = 0.001). Age over 70 at baseline was a predictive factor for nephrotoxicity, but not estimated glomerular filtration rate nor cisplatin-associated drugs. After a multivariate analysis, age remained a predictive factor for nephrotoxicity and IV/PO hydration associated with a decrease in nephrotoxic risk. CONCLUSION: The implementation of oral hydration in our practice was not associated with an increase in nephrotoxicity. Our observation based on large data from clinical practice shows that oral hydration after cisplatin is safe.
Authors: Christopher G Azzoli; Sherman Baker; Sarah Temin; William Pao; Timothy Aliff; Julie Brahmer; David H Johnson; Janessa L Laskin; Gregory Masters; Daniel Milton; Luke Nordquist; David G Pfister; Steven Piantadosi; Joan H Schiller; Reily Smith; Thomas J Smith; John R Strawn; David Trent; Giuseppe Giaccone Journal: J Clin Oncol Date: 2009-11-16 Impact factor: 44.544
Authors: Marcello Tiseo; Olga Martelli; Andrea Mancuso; Maria Pia Sormani; Paolo Bruzzi; Roberto Di Salvia; Filippo De Marinis; Andrea Ardizzoni Journal: Tumori Date: 2007 Mar-Apr